Broadly cross-reactive monoclonal antibodies define epitopes for vaccine development against HIV and other highly mutable viruses. Crystal structures are available for several such antibody-epitope complexes, but methods are needed to translate that structural information into immunogens that re-elicit similar antibodies. We describe a general computational method to design epitope-scaffolds in which contiguous structural epitopes are transplanted to scaffold proteins for conformational stabilization and immune presentation. Epitope-scaffolds designed for the poorly immunogenic but conserved HIV epitope 4E10 exhibited high epitope structural mimicry, bound with higher affinities to monoclonal antibody (mAb) 4E10 than the cognate peptide, and inhibited HIV neutralization by HIV+ sera. Rabbit immunization with an epitope-scaffold induced antibodies with structural specificity highly similar to mAb 4E10, an important advance toward elicitation of neutralizing activity. The results demonstrate that computationally designed epitope-scaffolds are valuable as structure-specific serological reagents and as immunogens to elicit antibodies with predetermined structural specificity.
INTRODUCTION
A protective HIV vaccine, or a universal flu vaccine, likely will elicit antibodies that block infection of diverse circulating strains of HIV or influenza. Several anti-HIV antibodies with broad neutralizing reactivities have been isolated from natural infection, and approximately 25% of HIV-1-infected individuals produce broadly neutralizing sera (for review, see Stamatatos et al., 2009 ), but efforts to elicit such responses by vaccination have failed. Anti-influenza broadly neutralizing antibodies (bNAbs) also have been characterized (Kashyap et al., 2008; Okuno et al., 1993; Sui et al., 2009; Throsby et al., 2008) , but the annual influenza vaccine elicits potent neutralizing antibodies only against the vaccine strains and closely related isolates.
The anti-HIV mAb 4E10 neutralizes 98% of HIV strains (Binley et al., 2004) ; hence, elicitation of 4E10-like antibodies is a major goal for HIV vaccine design. 4E10 binds a contiguous epitope in the membrane proximal external region (MPER) of gp41 just N-terminal to the transmembrane domain Zwick et al., 2001) , an epitope that is likely only transiently exposed during viral fusion with the target cell (Frey et al., 2008) . Nuclear magnetic resonance structural analysis of MPER peptides in lipid micelles found a kinked helix partially embedded in lipid (Sun et al., 2008) . Crystal structures of mAb 4E10 in complex with gp41 peptides revealed that 4E10 binds to a helical epitope in an end-on manner with the N terminus and one face of the helix docked into a hydrophobic cavity on the antibody; the bound epitope adopts a short 3/10 helix followed by an alpha helix, and conserved HIV side chains from both regions make significant antibody contacts (Cardoso et al., 2005 Scherer et al., 2010; Xu et al., 2009 ). The antibody also has a long, hydrophobic complementaritydetermining region H3 (CDR H3) loop, which does not bind directly to the helical epitope but which may provide contacts to the viral lipid membrane and contribute to neutralization (Cardoso et al., 2005 Scherer et al., 2010; Xu et al., 2009) . Here, as a first step to elicit antibodies with the binding and neutralizing properties of mAb 4E10, we aimed to develop immunogens that would elicit antibodies with the exact binding specificity of mAb 4E10 for its core peptide epitope.
A major hurdle confronting 4E10-vaccine design is that the epitope is naturally poorly immunogenic. While 4E10-like activity has been detected in HIV+ patients with broadly neutralizing activity, the frequency is low ($5%) (Binley et al., 2008; Li et al., 2009; Sather et al., 2009 ). Furthermore, previous attempts to elicit 4E10-like antibodies by vaccination using soluble trimeric gp140 (Derby et al., 2006) , VLP-membrane-anchored gp41 variants (Kim et al., 2007) , or a gp120 construct with the 4E10 epitope embedded in the highly immunogenic V2 loop (Law et al., 2007) , failed to elicit reactivity against the epitope primary sequence. MPER peptides anchored to liposomes or hepatitis B surface antigen particles have elicited modest responses against 4E10 peptides (Phogat et al., 2008; Watson and Szoka, 2009 ), but whether these responses were directed to the 4E10 epitope or other epitopes was not determined. In none of these cases was the helical epitope conformation necessarily stabilized, though in all cases the antigens did bind to mAb 4E10.
Crystallographic analysis of several anti-HIV (Calarese et al., 2003; Cardoso et al., 2005; Ofek et al., 2004; Zhou et al., 2007) and anti-influenza (Ekiert et al., 2009; Sui et al., 2009 ) bNAb/ epitope complexes, combined with advances in computational protein design , provides new opportunities for structure-based vaccine design (Dormitzer et al., 2008) . Here, we pursued a strategy of stabilizing an epitope in its antibody-bound conformation, and presenting that stabilized epitope in an immunogenic format, in order to elicit antibodies with structural specificity similar to the target antibody. Specifically, we engineered ''epitope-scaffold'' immunogens in which the HIV 4E10 epitope was transplanted by computational design to small, nonviral scaffold proteins for conformational stabilization and presentation to the immune system without the immunodominant variable regions typical of persistent pathogens. The computational design methods are general and should be applicable for structural stabilization of a variety of contiguous epitopes of different conformations from HIV, influenza, and other viruses.
RESULTS

Computational Design of Epitope-Scaffolds
We designed a total of 103 4E10 epitope-scaffolds by the sidechain grafting method (models representative of the variety of scaffold topologies are shown in Figure 1 ). This method entailed ''matching'' and ''design'' stages. In the automated ''matching'' stage, a subset of the Protein Data Bank (PDB) (Berman et al., 2000) was exhaustively searched for scaffold proteins with a surface-exposed backbone segment similar in conformation to the 4E10 epitope (NWFDITxxLW in PDB ID: 2FX7; Cardoso et al., 2007) . The resulting ''hits'' were filtered first by backbone clash with the antibody and second by antibody-epitope binding energy (epitope side chains were transferred to the scaffold and energy minimization (Gray et al., 2003) was used to optimize antibody and epitope side-chain conformations as well as the antibody-scaffold rigid-body orientation). Scaffolds selected in the ''matching'' stage were taken to the semiautomated design stage in which amino acids were designed for scaffold positions outside the epitope. The design stage aimed to ensure scaffold stability and solubility, avoid additional interactions between scaffold and antibody, support the optimized epitope side-chain conformations, eliminate undesired functional sites, and trim extraneous domains.
''Validated'' Epitope-Scaffolds Are Stable and Bind mAb 4E10 with High Affinity Epitope-scaffolds were expressed in Escherichia coli, purified by immobilized metal affinity chromatography and size-exclusion chromatography (SEC), and screened for 4E10 Fv binding in qualitative SEC assays. Constructs were validated if they expressed as soluble protein (not within inclusion bodies) and were purifiable to stable, soluble species that bound Fv by SEC; nonvalidated constructs were eliminated from further consideration. A total of 135 constructs were tested for expression (103 designs plus 32 purification tag variants), and, of those, 24 different designs (23% of 103 designs) were carried forward for quantitative analysis of mAb-binding by surface plasmon resonance (SPR). Biophysical data are collected in Table 1 for the representative set of 10 validated 4E10 epitope-scaffolds depicted in Figure 1 , and background information on each scaffold is provided in Table S1 (available online).
To facilitate interpretation of mAb 4E10-binding experiments, the epitope-scaffold solution multimer state and stoichiometry of Fv-binding were assessed by static light scattering (SLS) and SEC. Examples of SEC data are given in Figure S1 . Solution multimer state and Fv-binding stoichiometry accorded with expectation (monomer and 1:1, or dimer and 2:2 for T18) for 5 of 12 epitope-scaffolds (T18, T36, T93, T161, T278). The other epitope-scaffolds formed unexpected multimers that dissociated in the presence of Fv, suggesting that multimers self-associating through the hydrophobic 4E10 epitope were in equilibrium with rare monomers. Aggregation was noted previously for gp120 with engrafted MPER sequences (Law et al., 2007) . Multimerization of some 4E10 epitope-scaffolds will be addressed in detail in a separate manuscript (H.X., M.C. Clifton, M.A.H., Della J. Friend, T. B.-H., J.F.B.-J., J. Burgner, L.S., and R.K.S., unpublished data).
Epitope-scaffold affinities for mAb 4E10 were generally quite high. Antibody binding affinity and kinetics were assessed by SPR in two formats: with 4E10 Fv in solution as ''analyte'' and epitope-scaffolds coupled to the sensor chip as ''ligand'' (to assess interactions without avidity), and with 4E10 IgG captured on the chip and epitope-scaffold in solution (to allow avidity). Examples of SPR data and fits are shown in Figure S2 , and conditions for each SPR experiment are given in Table S2 . With epitope-scaffolds on the chip, equilibrium dissociation constants (K D ) ranged from 8 pM to 6 nM, and all epitopescaffolds bound 4E10 Fv more tightly than 4E10 peptides (K D = 10-20 nM) (Brunel et al., 2006; Xu et al., 2009) , gp41 (K D = 32-35 nM) (Klein et al., 2009) or gp140 trimers from isolate SF162 (K D = 130 nM) (Xu et al., 2009 ). The range of K D s was similar with epitope-scaffolds as analytes (22 pM to 3 nM). Monomeric epitope-scaffolds exhibited similar K D s in both formats, while 120-fold tighter binding due to bivalent avidity was detected for T88 (K D = 47 pM versus 5.6 nM) and 2.7-fold tighter binding was detected for T176 (K D = 51 pM versus 140 pM), consistent with stoichiometry data. In both formats, variations in both k on and k off contributed to variations in K D .
Epitope-scaffolds showed a range of thermal stabilities assessed by circular dichroism temperature melt analysis (T m = 44 C to T m R 100 C), though a majority (60%) were very stable with T m > 60 C, and a large majority (80%) were stable with T m > 50 C.
Crystallographic Analyses Reveal High Epitope Structural Mimicry by 4E10 Epitope-Scaffolds
To assess epitope structural mimicry, crystal structures were determined for six different epitope-scaffolds, four of unliganded epitope-scaffolds, and two of complexes with a 4E10 Fv construct biochemically validated elsewhere (Xu et al., 2009 ) ( Figure 2 ). Crystallization conditions are in Table S3 ; X-ray diffraction and refinement statistics are in Table 2 ; stereo images of electron density maps are given in Figure S3 . The overall conformations of the epitope-scaffolds agreed well with design models in five of six cases ( Figure 2A ), with backbone rmsd values between models and structures of 0.47, 0.50, 0.79, 1.14, and 1.26 Å for epitope-scaffolds T117, T18, T246, T93, and T161, respectively. The structure of the T88-Fv complex revealed an unintended domain-swapped dimer binding two Fv molecules, consistent with the 2:2 stoichiometry measured by SEC and SLS. Nevertheless both T88-Fv complexes were very similar to the design model; ignoring two residues that bridge the T88 dimer, backbone rmsd between the two Fv-monomer complexes and the model were 0.6 and 0.5 Å , respectively.
Most importantly, epitope mimicry was excellent in both Fv-bound and unbound epitope-scaffolds ( Figure 2B ). Backbone rmsd between epitope-scaffold and the 4E10-bound conformation of the gp41 peptide , computed over epitope residues 672-680, was 0.99, 0.31, 0.99, and 1.1 Å (B) Epitope structure (yellow tubes and sticks) from each of the epitope-scaffold crystal structures, superimposed with the 4E10 Fab-bound structure of a gp41 peptide (green tube and sticks) from PDB ID 2FX7 . Backbone rmsd values between epitope-scaffold and peptide are indicated for each superposition.
for the unbound structures of T18, T117, T161, and T246 respectively, 0.16 Å for each monomer in the T88-Fv complex, and 0.31 Å in the T93-Fv complex. B-factor analysis indicated that the epitope backbones were generally as well ordered as the epitope-scaffolds overall ( Figure S4 ). Side-chain mimicry was reduced in the unliganded structures ( Figure 2B ), but high affinities for Fv indicated that appropriate side-chain conformers were attainable. Indeed, intermolecular contacts within the unliganded crystals stabilized different epitope side-chain conformations at some positions ( Figure S5 ). The T88-Fv and T93-Fv complexes demonstrated precise mimicry at the sidechain level, with all-atom epitope rmsd of 0.48 and 0.36 Å , respectively; these complexes reproduced nearly all atomic contacts across the bNAb-peptide interface (Cardoso et al., 2005 Xu et al., 2009 ) but made some additional contacts (Tables S4-S6 and Figure S6 ).
Epitope-Scaffolds as Reagents Reveal That Neutralizing Activity in HIV+ Sera Has 4E10-Like Helical Specificity While Nonneutralizing Antipeptide Sera Does Not Sather et al. (2009) recently found evidence for the presence of 4E10-like antibodies in the serum of one HIV+ individual (''VC10028''). Support for this finding came primarily from the fact that a 4E10 peptide, but not a scrambled 4E10 peptide, could inhibit a fraction of the neutralizing activity of this serum in an in vitro neutralization assay. There are many potential antibody epitopes on the 4E10 peptide, especially given that the peptide likely samples many different conformations in solution, so the precise structural epitope(s) of the neutralizing antibodies in serum VC10028 could not be identified. Having demonstrated epitope structural mimicry crystallographically (Figure 2) , we employed 4E10 epitope-scaffolds as reagents to determine whether the epitope conformation stabilized on the scaffolds was a target of the cross-neutralizing antibodies in VC10028. Several epitope-scaffolds inhibited the neutralizing activity of the sera ( Figures 3A and 3B ), but no inhibition was detected by a ''dead-epitope'' version of one scaffold (X36) in which the ''WF'' of the epitope was mutated to ''ED'' ( Figure 3B ). These results demonstrated that neutralizing antibodies targeting the helical epitope structure targeted by mAb 4E10 were present in the VC10028 sera. In contrast, nonneutralizing rabbit sera elicited by a 4E10 peptide-KLH conjugate had no significant affinity for any of several epitope-scaffolds tested, even though the peptide-KLH sera bound avidly to 4E10 peptide itself ( Figure 4A ). This result demonstrated that while the 4E10 peptide-KLH conjugate was immunogenic (one of three rabbits produced peptide-specific antibodies), it did not elicit antibodies with structural specificity similar to 4E10. Indeed, comparison of peptide-KLH sera and mAb 4E10 binding to ala-scanned peptides (Bianchi et al., 2005) (Figures 4B and 4C ) confirms that the specificities are very different; mAb 4E10 binding is greatly diminished by mutants W672A, F673A, T676A, and L679A that remove critical contacts in the mAb/ peptide crystal structure (Cardoso et al., 2005 Xu et al., 2009 ), but peptide-KLH sera binding to those mutants is undiminished. Together, these results showed how epitopescaffolds may be useful as reagents to identify the presence or absence of precise structural specificities in sera and implied that epitope-scaffolds will be useful as ''bait'' to isolate antibodies targeting predefined structural epitopes.
An Epitope-Scaffold Elicited a Structurally Specific Antiepitope Response
The fact that the 4E10-like antibodies in serum VC10028 had structural specificity similar to mAb 4E10, while nonneutralizing antibodies in peptide-KLH sera did not, suggested that neutralization via the 4E10 epitope may require antibodies with 4E10-like structural specificity, and underscored the importance of testing epitope-scaffolds for their ability to re-elicit such structural specificity. To this end, we carried out immunization experiments with specific endotoxin-free preparations of one 4E10 epitope-scaffold (T88). Two groups of three rabbits were immunized with T88, one group with QS21 as adjuvant, and the other with PEI. One animal from each group developed antibodies that bound to HXB2 gp41, and this gp41-reactivity was inhibited by wild-type 4E10 peptide, demonstrating specific reactivity to the 4E10 epitope sequence ( Figure 5) . Further, the gp41-reactivity of the anti-T88 polyclonal sera from these two rabbits was inhibited by three different epitope-scaffolds tested (T36, T161, and T163) but not by a ''dead-epitope'' version of the T36 epitope-scaffold ( Figure 5 ), demonstrating specific reactivity to the helical structure of the 4E10 epitope stabilized on the scaffolds.
To assess the fine specificities of the anti-T88 polyclonal sera and mAb 4E10 across the helical epitope, we measured the binding of both sera and mAb to alanine-substituted 4E10 peptides using a multiplexed Luminex assay (Opalka et al., 2003) . The results are displayed in Figure 6 as ''relative avidity'' in which the avidity for each ala mutant is divided by the avidity of mAb 4E10 for the wild-type peptide. A relative avidity significantly less than 1.0 indicates engagement of a particular side chain, as mutations to alanine should not detract from peptide helical propensity. Strikingly, the results indicated that both T88 sera strongly engaged most epitope side chains transplanted onto the T88 scaffold, as relative avidities for ala mutants at gp41 positions 672-675 (WFDI) and L679 were less than 0.3 (p < 0.03 in all cases except sera2 at I675 where relative avidity was less than 0.4 with p = 0.02). Two transplanted epitope side chains (T676 and W680) were engaged by one of the sera but not both; T676 relative avidity was 0.33 ± 0.28 for sera1 (engaged with relative avidity < 0.7, p = 0.02) but 1.61 ± 0.33 for sera2, and W680 relative avidity was 0.49 ± 0.21 for sera2 (engaged with relative avidity < 0.8, p = 0.01) but 0.74 ± 0.50 for sera1. Relative avidities for mAb 4E10 showed a similar overall pattern of side-chain engagement, except that mAb 4E10 did not engage I675 (relative avidity, 1.35 ± 0.18) and did strongly engage T676 (relative avidity, 0.08 ± 0.05). The data for mAb 4E10 agreed with previous competitive ELISA experiments (Brunel et al., 2006) except at positions 675 and 680 where Luminex indicated no mAb engagement but competitive ELISA (Brunel et al., 2006) indicated moderate engagement. As expected, neither of the two T88 sera nor mAb 4E10 had significantly altered avidity for ala mutations of gp41 residues N677 and W678 that are located on the opposite face of the helix from the WFDITxxLW epitope of 4E10 and were not transplanted onto the T88 scaffold.
Gp41-specific IgG was purified from the anti-T88 polyclonal sera and tested for fine specificity and neutralization. The fine specificity of the gp41-specific IgG was consistent with that of the sera in Figure 6 . Neither the sera nor purified and concentrated anti-gp41 IgG reproducibly neutralized HIV-1 in an in vitro neutralization assay (not shown).
DISCUSSION
Here, we presented a new technique, computational design of epitope-scaffolds, to design immunogens that preserve the structure of a conserved epitope and expose that structure on a variety of different protein scaffolds with different immunologic backgrounds. We transplanted a conserved HIV epitope to multiple non-HIV proteins and succeeded to produce small, stable, soluble proteins with high affinity for the target monoclonal (K D s < 1 nM). Indeed, several epitope-scaffolds bound mAb 4E10 up to 1000-fold more strongly than cognate peptide (K D $10 pM for epitope-scaffolds versus 10 nM for peptide).
Crystal structures of multiple scaffolds demonstrated near perfect mimicry of the desired epitope backbone conformation (rmsd %1 Å ). We demonstrated the utility of epitope-scaffolds as serologic reagents to identify the presence or absence of antibodies targeting specific structural epitopes; this diagnostic utility conceptually extends to the use of epitope-scaffolds as ''bait'' for isolating such antibodies from libraries. Most importantly, we demonstrated that antibodies specific for the helical structure and the conserved side chains of the 4E10 epitope could be elicited by immunization with one such 4E10 epitopescaffold. In contrast, immunization with peptide-KLH failed to elicit this desired specificity, and previous studies showed that several different constructs competent for 4E10 binding failed to elicit any detectable reactivity to the 4E10 linear sequence (Derby et al., 2006; Kim et al., 2007; Law et al., 2007) . This example suggests the potential power of epitope-scaffolding; with the technique described here, many types of contiguous epitopes could be transplanted onto scaffolds for structural stabilization and immune presentation, and epitope-structurespecific immune responses might be further enhanced by glycan or PEG masking of the scaffold, by multimeric, oriented display of epitope-scaffolds on particles, by heterologous prime-boost immunizations, or combinations thereof. We also note that the epitope-scaffold concept is not limited to scaffolding of antibody epitopes, it could also prove useful to study, or design inhibitors for, peptide-protein and protein-protein interactions.
To our knowledge, the antibodies elicited by T88 are the first induced by vaccination to possess structural specificity highly similar to that of 4E10. This is an important advance for HIV vaccine design, because the helical specificity possessed by 4E10 and also the neutralizing sera in VC10028 (Sather et al., Anti-T88 sera from two rabbits (blue, PEI adjuvant, five immunizations; red, QS21 adjuvant, six immunizations) binds to gp41 (''Sera alone''). Addition of peptide (''Sera+peptide'') or different scaffolds (''Sera+T161,'' ''Sera+T163,'' ''Sera+T36'') significantly reduces gp41vbinding, but addition of a ''deadepitope'' epitope-scaffold (''Sera+X36'') does not. ELISA response of prebleed rabbit sera to gp41 was subtracted from the data. Data were averaged from two or four experiments; error bars represent means ± SD.
2009) is likely necessary for neutralization via the 4E10 epitope. The T88 antisera elicited by these first-generation designs did not neutralize HIV, however, indicating that helical specificity and the engagement of the conserved side chains of the 4E10 peptide epitope may not be sufficient. This result is consistent with recent studies demonstrating that specific hydrophobic residues on the tip of the 4E10 CDRH3 are required for maximum potency neutralization: alanine (Alam et al., 2009; Scherer et al., 2010; Xu et al., 2009 ) and aspartic acid (Scherer et al., 2010) substitutions at the tip do not significantly reduce gp41 or epitope-peptide binding, but they do reduce both lipid binding (Alam et al., 2009; Scherer et al., 2010; Xu et al., 2009 ) and the extraction of the epitope from the membrane (Xu et al., 2009) , either mechanism potentially contributing to neutralization potency. As mentioned above, the tip of the 4E10 CDRH3 does not contact the peptide epitope used as the basis of the design of these first-generation epitope-scaffolds (Cardoso et al., 2005 Xu et al., 2009) ; further, no contacts with the CDRH3 tip are seen in Fv 4E10/epitope-scaffold complex structures as this was not a design criteria. Next-generation epitope-scaffolds incorporating higher order structural complementarity, such as viral membrane lipid structures, will be employed to improve on this approach.
In summary, we introduced a computational methodology that allows the faithful transplantation of conformational epitopes into distinct protein platforms and demonstrated that this leads to the appropriate stimulation of humoral responses to a conserved, but intrinsically poorly immunogenic viral epitope. Epitope-scaffolds therefore expand the universe of immunogens available for vaccine research. For the case of 4E10, computationally designed scaffolds can next be presented to the immune system in the context of lipid membrane surfaces, in combination with specific adjuvants to elicit antibodies with expanded recognition and neutralization properties. Relative avidity for bNAb 4E10 (black) and two different anti-T88 rabbit sera (blue, PEI adjuvant; red, QS21 adjuvant) quantifies the avidity of each antibody/peptide or antisera/peptide pair relative to bNAb 4E10 binding to wild-type 4E10 peptide. Both anti-T88 antisera exhibit low relative avidity for mutants W672A, F673A, D674A, I675A, and L679A, which indicates that the antisera strongly engaged the 4E10 side chains at those positions on the helical epitope. Data were averaged from five experiments each run in duplicate; error bars represent mean ± SD.
The matching stage exhaustively searched 13337 single chains from the PDB (Berman et al., 2000) for backbone similarity with the 4E10 epitope by computing rmsd between residues 671-680 or 672-680 in PDB ID:2FX7 and all possible protein segments using matched-width sliding windows in the query scaffolds. All hits with rmsd <1 Å (or rmsd/length <0.1) were retained if backbone clash with antibody was less than 100 score units. Epitope side chains were transferred to allglycine versions of the remaining hits, and then interfacial side-chain torsions and the rigid-body orientation of antibody and epitope-scaffold were optimized by minimization (Gray et al., 2003) . Highly conserved epitope side chains W672, F673, I675, L679, and W680 were transplanted to all scaffolds. At moderately variable epitope positions (671, 674, 676) , the most energetically favorable of the common HIV side chains was generally transplanted (N, S, or G at 671; D, S, or N at 674; S or T at 676) . Native scaffold side-chain rotamers outside the epitope were recovered, and residues near (heavy atom distance <4 Å ) the epitope or the antibody were designed, categorized as ''intra'' and ''inter'' positions, respectively. Inter residues were allowed to be ALA, GLY, SER, and THR, and intra positions were allowed to be all amino acids except CYS. Epitope-scaffolds were ranked by antibody binding energy and human-guided design was performed on the best to a) revert unnecessary or potentially destabilizing mutations; b) eliminate unpaired cysteines and undesired functional sites; c) trim extraneous domains; and d) optimize solubility. In two cases (T93 and T278), more advanced flexible backbone design was performed for domain trimming (T93) or fusion to maltose binding protein (MBP) for stabilization (T278); discussion of these methods is beyond the scope of this manuscript and will be reported elsewhere (B.E.C. , Y.-E.A.B., D.J. Friend, K.E., H.X., E.B., T.B.-H., J.F.B.-J., L.S., R.K.S., and W.R.S., unpublished data).
Protein Expression, Purification, and Characterization DNA segments encoding epitope-scaffold constructs were synthesized with optimized codon usage and RNA structure (Codon Devices, Genscript Corp.), subcloned into pET29 (EMD Biosciences), and transformed into BL-21 Star E. coli (Invitrogen). Single colonies were expanded from starter cultures in Luria Broth into ZYP-5052 autoinduction media (Studier, 2005) plus kanamycin (100 mg/ml), incubated for 4 hr at 37 C and then overnight at 18 C. Cultures were then pelleted and stored at À20 C. Pellets were resuspended in standard buffer (50 mM Tris, 500 mM NaCl, 10 mM imidazole, 0.5 mg/ml lysozyme), sonicated on ice, and clarified by centrifugation. Supernatants were tumbled with 10 ml of nickel-NTA resin (Superflow NTA, QIAGEN) for 30 min at 4 C. The resin was then rinsed twice with 10 mM imidazole, once with standard buffer plus 20 mM imidazole and eluted with standard buffer plus 250 mM imidazole. Eluates were concentrated by ultrafiltration (Amicon Ultra, Millipore) and filtered through 0.22 mm Ultrafree-MC spin columns (Millipore). Epitope-scaffolds were then purified by preparative size exclusion chromatography (SEC) on Superdex 75 16/60 columns (GE Healthcare) at room temperature in 25 mM PIPES (pH 7.0), 150 mM NaCl, 1 mM EDTA, and 0.02% w/w sodium azide (PNEA). Epitope-scaffold purity was confirmed by SDS-PAGE and analytical SEC; analytical SEC ± target NAb (Superdex 75 or 200 10/30 columns, GE Healthcare) in PNEA was used to assay qualitative binding, multimer state, monodispersivity, and complex stoichiometries. Protein concentrations were determined with the BCA protein assay (Pierce); solution thermostabilities (T m ) were determined by circular dichroism (CD) spectroscopy with Jasco J-815 instrumentation as previously described (Xu et al., 2009) . In order to prepare endotoxin-free protein for immunization studies, bacterial pellets were alternately resuspended in detergent buffer (50 mM NaH 2 PO 4 , 500 mM NaCl, 10 mM imidazole, 0.5 mg/ml lysozyme, 0.01 mg/ml DNase, 0.1% Triton X114) and loaded IMAC resin was alternately initially washed in 10 mM imidazole, 50 mM NaH 2 PO 4 , 500 mM NaCl, 0.1% Triton X114.
Preparative SEC purification was carried out in sterile PBS on columns just previously cleaned with a bolus of 1 M NaOH. Endotoxin levels were assayed with the PyroGene Recombinant Factor C Endotoxin Detection System (Lonza). Protein preparations were further purified using the ProteoSpin Endotoxin Removal Maxi Kit (Norgen) if endotoxin levels exceeded 2EU/50 mg at a protein concentration of 1 mg/ml, the maximum level accepted for immunization.
Crystallization and Crystallography
Crystals of epitope-scaffolds and epitope-scaffold-Fv complexes were grown by vapor diffusion, under the conditions shown in Table S3 . The complexes were purified as such by SEC prior to crystallization. Diffraction data were collected at À170 C on cryopreserved crystals, as detailed in Table 2 , and processed with d*TREK (Pflugrath, 1999) . Initial structure factor phases were determined by molecular replacement (search models in Table S3 ), using the program Phaser (McCoy et al., 2007) or MolRep (Vagin and Teplyakov, 1997) , as implemented under CCP4i (Potterton et al., 2003) . Successive rounds of modeling and positional and individual B factor refinement were carried out with Coot (Emsley and Cowtan, 2004) and Refmac5 (Murshudov et al., 1997) . Five of the six structures were submitted to the TLSMD server Merritt, 2006a, 2006b) where TLS groups were defined. Structure validation was carried out with Procheck (Laskowski et al., 1993) , the MolProbity server (Davis et al., 2007) , and the RCSB ADIT validation server. The structures were deposited in the PDB (Berman et al., 2000) with accession codes in Table S3 . Data collection and structure refinement statistics are in Table 2 .
Luminex Multiplex Assay 4E10 peptides with three lysines added to their C termini were amine-coupled to Bio-plex beads (Biorad, CA) (12 mg peptide/100 ml beads) as described by the manufacturer's protocol. Serially diluted sera (pre-and postimmunization) or mAb 4E10 were incubated with the bead cocktail for 1 hr at room temperature. After four washes, beads were incubated with anti-rabbit or human PE-conjugated secondary Ab for 1 hr at room temperature. A final wash step was performed prior to analysis on a Luminex 200 System (Invitrogen). Relative avidity was computed by subtracting peptide-matched, prebleed mean fluorescent intensity (MFI) from each sample MFI and then normalizing to the experiment-matched MFI for bNAb 4E10 binding to wild-type 4E10 peptide.
Peptide ELISA Binding of rabbit sera or bNAb 4E10 to 4E10 peptide (NWFDITNWLWYIRKKK) (Derby et al., 2006) , alanine mutant 4E10 peptides, and epitope-scaffolds was assessed by ELISA as previously described (Derby et al., 2006) .
Epitope-Scaffold Competitive ELISA Rabbit sera (1:25) were incubated with epitope-scaffolds (100 mg/ml) for 1 hr, and then the mixture was added to ELISA plates coated with recombinant gp41 (HxB2) (0.5 mg/ml) (Meridian Life Science) for 90 min at 37 C. The binding of antibodies to gp41 was detected as above for the peptide ELISA.
Competing the Neutralizing Activity of HIV-1 + Sera by Epitope-Scaffolds Epitope-scaffolds were tested for their ability to inhibit the neutralizing activity of plasma VC10028 as previously described for peptide inhibition (Sather et al., 2009 ).
Immunizations
Rabbits were immunized monthly at the Pocono Rabbit Farm and Laboratory Inc. (Canadensis, PA) with epitope-scaffolds mixed in PEI (Polysciences, Inc.) or QS21 (Antigenics, Inc); 0.2 mg protein in 0.2 ml of PBS was administered into the two hind legs (0.2 ml per injection site). KLH peptide immunizations were performed by GenScript Corp (Piscataway, NJ); rabbits were immunized with 0.5 mg KLH peptide and complete Freund's adjuvant, and boosted at weeks 2, 5, and 8 with 0.5 mg KLH peptide and incomplete Freund's adjuvant. KLH peptide sera were tested from day 0 and week 10.
Statistical Analyses
We performed statistical analyses using a one-tailed Student's t test to obtain p values on the significance of relative avidity levels below specified thresholds.
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